Generic Injectables Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Apr-2020 | List of Tables : 106 | List of Figures : 88 | No. of Pages : 170 | Report Code : FACT4681MR | Format :

Low Investment Costs to Heighten Generic Injectables Market Growth Prospects

Developing branded formulations is a time-consuming and expensive process. The average time required to develop a new chemical entity is a decade. A cost of US$ 5-8 Bn is incurred in the development of drug formulations, owing to stringent government regulations that ensure safety and efficacy of preclinical and clinical trials. In comparison, development of generic drugs is an inexpensive process. This is because they are exempted from the requirement to conduct clinical trials and toxicity studies.

Governments worldwide are encouraging distribution and development of generic drugs so as to make them available to a larger populace, particularly rural people in the developing countries. Based on these trends, the global generic injectables market is forecast to expand impressively at a CAGR of 13.3% during the forecast period (2020-2025). It is expected to reach a value of US$ 1.5 Bn by 2025-end. Moreover, expiry of blockbuster injectable molecules patents, research and development of large molecule generic injectables and strong pipeline of products are also anticipated to boost the market.

However, supply-chain disruptions in the wake of restricted air and water transport may prove to be a hindrance to the growth of the genetic injectables market.

Large Molecular Injectables to Register Stellar Growth

The large molecular injectables segment is projected to capture lion’s share in the global generic injectables market, accounting for 3/5th of the total market value. Rising demand for affordable biological products, accelerated research and development activities for biosimilar products and expected patent expiry of blockbuster molecules by 2020 are key drivers. Large molecular injectable drugs are anticipated to expand at a stellar CAGR of 34.8% during the forecast period.

At the same time, the small molecular injectables segment shall hold a little over two-fifth of the generic injectables market. Increase in incidence of infectious diseases in developing countries, greater affordability and easy availability are key growth influencers. Moreover, the small molecular injectable drugs have widespread usage in the treatment of oncology disorders, infectious diseases, blood diseases and cardiovascular diseases.

generic injectables market analysis and forecast by product type

Get in-depth insights on global generic injectables by requesting for a report sample here

Asia-Pacific Remains the Kingpin, North America Second-Most Lucrative Market

Asia-Pacific shows prolific growth opportunities for the global generic injectables market throughout the forecast period. High demand for injectable antibiotics in the wake of high prevalence of infectious diseases such as diarrhea, typhoid, malaria and cholera; increasing prevalence of cancer; high demand for inexpensive medicines and a large market presence by key players are anticipated to leverage the growth in the Asia-Pacific. Projections indicate a staggering CAGR of 16.1%, capturing a market share of almost two-fifths of the overall global generic injectables market.

North America is projected to be the second-most lucrative market for generic injectables. This is mostly because of increase in the number of abbreviated new drug application (ANDA) approvals, rising demand for inexpensive biosimilar products and rising prevalence of lifestyle diseases. Projections indicate a robust CAGR of 11.4% during the forecast period.

Competitors Leveraging on New Pipeline Drugs to Gain Hegemony

Several key players operate in the global generic injectables market. These include Pfizer, Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC., Lupin Ltd., Sanofi and Biocon. The core focus of all market players is on the development of generic biological products, or biosimilars.

Pfizer Inc., dominates the global generic injectables market, holding one-tenth of the total market share. It is the leading biosimilars company in the world and has consolidated its position through the advancement of six biosimilar pipeline products. Currently, the company is in the process of developing a formula titled PF-06881894, a biosimilar to Neulasta® for oncology practitioners. Likewise, it is also developing a biosimilar for Rheumatoid Arthritis titled PF-06410293. Additionally, it has also developed Pfizerpen, a Penicillin G Potassium powder used as an antibiotic injection for intramuscular, continuous intravenous drip and intrathecal administration.

Sandoz Inc. is estimated to hold 1/20th of the global generic injectables market share. It also offers a strong biosimilar drugs pipeline. Its portfolio includes both blockbuster and niche products for all major therapeutic areas. Its generic drugs division includes Glatopa-based formulae such as Gilenya®, Afintor® and Glivec®. Sandoz operates globally through three franchises: retail generics, anti-infectives and biopharmaceuticals.

generic injectables market competitive analysis

To get an exhaustive overview of competition landscape of generic injectables, ask an analyst here

COVID-19 Impact Analysis:

Several regions across the world have expressed concerns over the supply of generic injectable biosimilars running short. This is attributed to reduced availability of international air transportation and a significant increase in shipping expenses. Countries such as the United States have pointed out that reduction in availability of international shipping will prove expensive, particularly for critical medicines. Rising shipping costs is anticipated to prove detrimental to the operations of smaller companies, as well as consumers who depend on these drugs for their health problems.

Dearth of information has made it difficult for various pharmaceutical companies and service providers to diagnose the potential impact COVID-19 has had on their operations. The rising number of COVID-19 infections on a daily basis has rendered healthcare providers embroiled in a deep quagmire of lack of adequate solutions. Nevertheless, there exists a silver lining in the generic injectables market. Generic-drug pricing may leverage in the short-run, owing to scarcity created by supply-chain disruptions. This will prompt consumers to pay a higher price for the drugs in the long-run in order to secure their supply.

Global Generic Injectables Market- Scope of the Report

The recent study by Fact.MR on global generic injectables market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that are currently determining the growth of generic injectables market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of generic injectables. The study also provides dynamics that are responsible for influencing the future status of the global generic injectables market over the forecast period.

A detailed assessment of the global generic injectables market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global generic injectables market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Generic Injectables Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global generic injectables market across the globe.

A comprehensive estimate of the global generic injectables market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global generic injectables market during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Generic Injectables: Market Segmentation

Fact.MR has studied the global generic injectables market with detailed segmentation on the basis of product type, container type, application and key regions.

Product Type

Container Type

Application

Key Regions

Large Molecule Injectables:

mAb

Insulin

Others

Vials

Oncology

North America

Small Molecule Injectables

Ampoules

Infectious diseases

Europe

 

Premix

Cardiology

Asia Pacific

 

Prefilled syringes

Diabetes

Eastern Europe

 

Others

Immunology

Latin America

 

 

Others

Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Generic Injectables Market: Analysis on Market Size Evaluation

The global generic injectables market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for generic injectables is available in terms of “US$ Mn” for value and thousand units for volume. A Y-o-Y growth contrast on prominent generic injectables market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Generic Injectables Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global generic injectables report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global generic injectables market during the forecast period.

Country-specific valuation on demand for generic injectables has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

Global Generic Injectables Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global generic injectables along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global generic injectables, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio and key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global generic injectables market. Prominent manufacturers with established market presence in the global generic injectables market are Pfizer, Inc., Sandoz, Inc. (Novartis AG), Fresenius Kabi AG, Mylan N.V, Teva Pharmaceutical Industries Ltd., Sagent Pharmaceutical Ltd., Hikma Pharmaceuticals Plc and Sanofi Ltd.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Generic Injectable Market Size (US$ Mn) and Forecast, by Region, 2020 and 2025

    3.2. Global Generic Injectables Market: Market Snapshot

4. Market Overview

    4.1. Global Generic Injectables Market Overview

    4.2. Global Generic Injectables Market Key Industry Developments

5. Market Dynamics

    5.1. Drivers and Restraints Snapshot Analysis

    5.2. Drivers

    5.3. Restraints

    5.4. Opportunities

    5.5. Key Trends

    5.6. Global Generic Injectables Market Revenue Projections (US$ Mn), 2020–2025

    5.7. Global Generic Products Penetration Overview: by Key Countries

    5.8. Biosimilars: Pipeline Analysis

    5.9. Generic Injectables Market: Mergers & Acquisitions

    5.10. EU and USFDA Approved Biosimilar Products Snapshot

    5.11. Challenges Faced by Biosimilar Product to be Approved in U.S. Market

    5.12. Regulatory Framework

    5.13. Heat Map Analysis - Company

6. Global Generic Injectables Market Analysis, by Product Type

    6.1. Introduction

    6.2. Key Insights

    6.3. Global Generic Injectables Market Size and Forecast, by Product Type

        6.3.1. Large Molecule Injectables

            6.3.1.1. Monoclonal Antibodies (mAbs)

            6.3.1.2. Insulin

            6.3.1.3. Others

        6.3.2. Small Molecule Injectables

    6.4. Global Generic Injectables Market Analysis, by Product Type

    6.5. Global Generic Injectables Market Attractiveness Analysis, by Product Type

7. Global Generic Injectables Market Analysis, by Container Type

    7.1. Introduction

    7.2. Key Insights

    7.3. Global Generic Injectables Market Size and Forecast, by Container Type

        7.3.1. Vials

        7.3.2. Premix

        7.3.3. Prefilled Syringes

        7.3.4. Ampoules

        7.3.5. Other

    7.4. Global Generic Injectables Market Analysis, by Container Type

    7.5. Global Generic Injectables Market Attractiveness Analysis, by Container Type

8. Global Generic Injectables Market Analysis, by Application

    8.1. Introduction

    8.2. Key Insights

    8.3. Global Generic Injectables Market Size and Forecast, by Application

        8.3.1. Oncology

        8.3.2. Infectious diseases

        8.3.3. Cardiology

        8.3.4. Diabetes

        8.3.5. Immunology

        8.3.6. Others

    8.4. Global Generic Injectables Market Analysis, by Application

    8.5. Global Generic Injectables Market Attractiveness Analysis, by Application

9. Global Generic Injectables Market Analysis, by Route of Administration

    9.1. Introduction

    9.2. Key Insights

    9.3. Global Generic Injectables Market Size and Forecast, by Route of Administration

        9.3.1. Intravenous

        9.3.2. Intramuscular

        9.3.3. Subcutaneous

        9.3.4. Others

    9.4. Global Generic Injectables Market Analysis, by Route of Administration

    9.5. Global Generic Injectables Market Attractiveness Analysis, by Route of Administration

10. Global Generic Injectables Market Analysis, by Region

    10.1. Introduction

    10.2. Key Insights

    10.3. Global Generic Injectables Market Size and Forecast , by Region, 2014–2025

        10.3.1. North America

        10.3.2. Europe

        10.3.3. Asia Pacific

        10.3.4. Latin America

        10.3.5. Middle East & Africa

    10.4. Global Generic Injectables Market Analysis, by Region

    10.5. Global Generic Injectables Market Attractiveness Analysis, by Region

11. North America Generic Injectables Market Analysis

    11.1. North America Generic Injectables Market Key Findings

    11.2. North America Generic Injectables Market Overview

    11.3. North America Generic Injectables Market Size and Forecast, by Product Type

        11.3.1. Large Molecule Injectables

            11.3.1.1. Monoclonal Antibodies (mAbs)

            11.3.1.2. Insulin

            11.3.1.3. Others

        11.3.2. Small Molecule Injectables

        11.3.3. North America Generic Injectables Market Analysis, by Product Type

    11.4. North America Generic Injectables Market Size and Forecast, by Container Type

        11.4.1. Vials

        11.4.2. Premix

        11.4.3. Prefilled Syringes

        11.4.4. Ampoules

        11.4.5. Other

    11.5. North America Generic Injectables Market Size and Forecast, by Application

        11.5.1. Oncology

        11.5.2. Infectious diseases

        11.5.3. Cardiology

        11.5.4. Diabetes

        11.5.5. Immunology

        11.5.6. Others

    11.6. North America Generic Injectables Market Size and Forecast, by Route of Administration

        11.6.1. Intravenous

        11.6.2. Intramuscular

        11.6.3. Subcutaneous

        11.6.4. Others

    11.7. North America Generic Injectables Market Forecast, by Country

        11.7.1. U.S.

        11.7.2. Canada

    11.8. North America Generic Injectables Market Attractiveness Analysis 

        11.8.1. By Product Type

        11.8.2. By Container Type

        11.8.3. By Application

        11.8.4. By Route of Administration

        11.8.5. By Country

12. Europe Generic Injectables Market Analysis

    12.1. Europe Generic Injectables Market Key Findings

    12.2. Europe Generic Injectables Market Overview

    12.3. Europe Generic Injectables Market Size and Forecast, by Product Type

        12.3.1. Large Molecule Injectables

            12.3.1.1. Monoclonal Antibodies (mAbs)

            12.3.1.2. Insulin

            12.3.1.3. Others

        12.3.2. Small Molecule Injectables

    12.4. Europe Generic Injectables Market Size and Forecast, by Container Type

        12.4.1. Vials

        12.4.2. Premix

        12.4.3. Prefilled Syringes

        12.4.4. Ampoules

        12.4.5. Other

    12.5. Europe Generic Injectables Market Size and Forecast, by Application

        12.5.1. Oncology

        12.5.2. Infectious diseases

        12.5.3. Cardiology

        12.5.4. Diabetes

        12.5.5. Immunology

        12.5.6. Others

    12.6. Europe Generic Injectables Market Size and Forecast, by Route of Administration

        12.6.1. Intravenous

        12.6.2. Intramuscular

        12.6.3. Subcutaneous

        12.6.4. Others

    12.7. Europe Generic Injectables Market Forecast, by Country

        12.7.1. Germany

        12.7.2. U.K.

        12.7.3. France

        12.7.4. Spain

        12.7.5. Italy

        12.7.6. Rest of Europe

    12.8. Europe Generic Injectables Market Attractiveness Analysis

        12.8.1. By Product Type

        12.8.2. By Container Type

        12.8.3. By Application

        12.8.4. By Route of Administration

        12.8.5. By Country

13. Asia Pacific Generic Injectables Market Analysis

    13.1. Asia Pacific Generic Injectables Market Key Findings

    13.2. Asia Pacific Generic Injectables Market Overview

    13.3. Asia Pacific Cytometry Market Size and Forecast, by Product Type

        13.3.1. Large Molecule Injectables

            13.3.1.1. Monoclonal Antibodies (mAbs)

            13.3.1.2. Insulin

            13.3.1.3. Others

        13.3.2. Small Molecule Injectables

    13.4. Asia Pacific Generic Injectables Market Size and Forecast, by Container Type

        13.4.1. Vials

        13.4.2. Premix

        13.4.3. Prefilled Syringes

        13.4.4. Ampoules

        13.4.5. Other

    13.5. Asia Pacific Generic Injectables Market Size and Forecast, by Application

        13.5.1. Oncology

        13.5.2. Infectious diseases

        13.5.3. Cardiology

        13.5.4. Diabetes

        13.5.5. Immunology

        13.5.6. Others

    13.6. Asia Pacific Generic Injectables Market Size and Forecast, by Route of Administration

        13.6.1. Intravenous

        13.6.2. Intramuscular

        13.6.3. Subcutaneous

        13.6.4. Others

    13.7. Asia Pacific Generic Injectables Market Forecast, by Country

        13.7.1. China

        13.7.2. India

        13.7.3. Japan

        13.7.4. Australia & New Zealand

        13.7.5. Rest of Asia Pacific

    13.8. Asia Pacific Generic Injectables Market Attractiveness Analysis 

        13.8.1. By Product Type

        13.8.2. By Container Type

        13.8.3. By Application

        13.8.4. By Route of Administration

        13.8.5. By Country

14. Latin America Generic Injectables Market Analysis

    14.1. Latin America Generic Injectables Market Key Findings

    14.2. Latin America Generic Injectables Market Overview

    14.3. Latin America Cytometry Market Size and Forecast, by Product Type

        14.3.1. Large Molecule Injectables

            14.3.1.1. Monoclonal Antibodies (mAbs)

            14.3.1.2. Insulin

            14.3.1.3. Others

        14.3.2. Small Molecule Injectables

    14.4. Latin America Generic Injectables Market Size and Forecast, by Container Type

        14.4.1. Vials

        14.4.2. Premix

        14.4.3. Prefilled Syringes

        14.4.4. Ampoules

        14.4.5. Other

    14.5. Latin America Generic Injectables Market Size and Forecast, by Application

        14.5.1. Oncology

        14.5.2. Infectious diseases

        14.5.3. Cardiology

        14.5.4. Diabetes

        14.5.5. Immunology

        14.5.6. Others

    14.6. Latin America Generic Injectables Market Size and Forecast, by Route of Administration

        14.6.1. Intravenous

        14.6.2. Intramuscular

        14.6.3. Subcutaneous

        14.6.4. Others

    14.7. Latin America Generic Injectables Market Forecast, by Country

        14.7.1. Brazil

        14.7.2. Mexico

        14.7.3. Rest of Latin America

    14.8. Latin America Generic Injectables Market Attractiveness Analysis

        14.8.1. By Product Type

        14.8.2. By Container Type

        14.8.3. By Application

        14.8.4. By Route of Administration

        14.8.5. By Country

15. Middle East & Africa Generic Injectables Market Analysis

    15.1. Middle East & Africa Generic Injectables Market Key Findings

    15.2. Middle East & Africa Generic Injectables Market Overview

    15.3. Middle East & Africa Cytometry Market Size and Forecast, by Product Type

        15.3.1. Large Molecule Injectables

            15.3.1.1. Monoclonal Antibodies (mAbs)

            15.3.1.2. Insulin

            15.3.1.3. Others

        15.3.2. Small Molecule Injectables

    15.4. Middle East & Africa Generic Injectables Market Size and Forecast, by Container Type

        15.4.1. Vials

        15.4.2. Premix

        15.4.3. Prefilled Syringes

        15.4.4. Ampoules

        15.4.5. Other

    15.5. Middle East & Africa Generic Injectables Market Size and Forecast, by Application

        15.5.1. Oncology

        15.5.2. Infectious diseases

        15.5.3. Cardiology

        15.5.4. Diabetes

        15.5.5. Immunology

        15.5.6. Others

    15.6. Middle East & Africa Generic Injectables Market Size and Forecast, by Route of Administration

        15.6.1. Intravenous

        15.6.2. Intramuscular

        15.6.3. Subcutaneous

        15.6.4. Others

    15.7. Middle East & Africa Generic Injectables Market Size and Forecast, by Country

        15.7.1. GCC Countries

        15.7.2. Israel

        15.7.3. South Africa

        15.7.4. Rest of Middle East & Africa

    15.8. Middle East Generic Injectables Market Attractiveness Analysis

        15.8.1. By Product Type

        15.8.2. By Container Type

        15.8.3. By Application

        15.8.4. By Route of Administration

        15.8.5. By Country

16. Competition Landscape

    16.1. Global Generic Injectables Market Share Analysis, by Company (2018)

    16.2. Company Profiles

        16.2.1. Pfizer Inc.

            16.2.1.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.1.2. Financials

            16.2.1.3. Recent Developments

            16.2.1.4. Strategy

        16.2.2. Novartis AG (Sandoz International GmbH)

            16.2.2.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.2.2. Financials

            16.2.2.3. Recent Developments

            16.2.2.4. Strategy

        16.2.3. Baxter

            16.2.3.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.3.2. Financials

            16.2.3.3. Recent Developments

            16.2.3.4. Strategy

        16.2.4. Fresenius SE & Co. KGaA

            16.2.4.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.4.2. Financials

            16.2.4.3. Recent Developments

            16.2.4.4. Strategy

        16.2.5. Mylan N.V.

            16.2.5.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.5.2. Financials

            16.2.5.3. Recent Developments

            16.2.5.4. Strategy

        16.2.6. Teva Pharmaceutical Industries Ltd.

            16.2.6.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.6.2. Financials

            16.2.6.3. Recent Developments

            16.2.6.4. Strategy

        16.2.7. Hikma Pharmaceuticals PLC.

            16.2.7.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.7.2. Financials

            16.2.7.3. Recent Developments

            16.2.7.4. Strategy

        16.2.8. Lupin Ltd.

            16.2.8.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.8.2. Financials

            16.2.8.3. Recent Developments

            16.2.8.4. Strategy

        16.2.9. Sanofi

            16.2.9.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.9.2. Financials

            16.2.9.3. Recent Developments

            16.2.9.4. Strategy

        16.2.10. Biocon

            16.2.10.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.10.2. Financials

            16.2.10.3. Recent Developments

            16.2.10.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Generic Injectables Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025